vs
Apellis Pharmaceuticals, Inc.（APLS）与BANK OF HAWAII CORP（BOH）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是BANK OF HAWAII CORP的1.0倍（$199.9M vs $192.3M），BANK OF HAWAII CORP净利率更高（29.9% vs -29.5%，领先59.4%），过去两年BANK OF HAWAII CORP的营收复合增速更高（10.7% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
夏威夷银行是美国夏威夷州的区域性商业银行，总部位于檀香山，是夏威夷第二古老的银行，也是当地最大的本土银行，多数表决权股东均居住在州内。该行的账户数、客户规模、营业网点及ATM数量均居夏威夷金融机构首位，业务涵盖零售银行、商业银行、投资服务、资金运营四大板块。
APLS vs BOH — 直观对比
营收规模更大
APLS
是对方的1.0倍
$192.3M
净利率更高
BOH
高出59.4%
-29.5%
两年增速更快
BOH
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $192.3M |
| 净利润 | $-59.0M | $57.4M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 29.9% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | 30.6% |
| 每股收益（稀释后） | $-0.40 | $1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSBOH
| Q1 26 | — | $192.3M | ||
| Q4 25 | $199.9M | $189.6M | ||
| Q3 25 | $458.6M | $182.6M | ||
| Q2 25 | $178.5M | $174.5M | ||
| Q1 25 | $166.8M | $169.9M | ||
| Q4 24 | $212.5M | $163.2M | ||
| Q3 24 | $196.8M | $162.7M | ||
| Q2 24 | $199.7M | $156.9M |
净利润APLSBOH
| Q1 26 | — | $57.4M | ||
| Q4 25 | $-59.0M | $60.9M | ||
| Q3 25 | $215.7M | $53.3M | ||
| Q2 25 | $-42.2M | $47.6M | ||
| Q1 25 | $-92.2M | $44.0M | ||
| Q4 24 | $-36.4M | $39.2M | ||
| Q3 24 | $-57.4M | $40.4M | ||
| Q2 24 | $-37.7M | $34.1M |
营业利润率APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 40.9% | ||
| Q3 25 | 48.7% | 37.1% | ||
| Q2 25 | -18.6% | 34.6% | ||
| Q1 25 | -50.0% | 33.1% | ||
| Q4 24 | -12.3% | 31.6% | ||
| Q3 24 | -24.0% | 32.3% | ||
| Q2 24 | -14.7% | 28.9% |
净利率APLSBOH
| Q1 26 | — | 29.9% | ||
| Q4 25 | -29.5% | 32.1% | ||
| Q3 25 | 47.0% | 29.2% | ||
| Q2 25 | -23.6% | 27.3% | ||
| Q1 25 | -55.3% | 25.9% | ||
| Q4 24 | -17.1% | 24.0% | ||
| Q3 24 | -29.2% | 24.8% | ||
| Q2 24 | -18.9% | 21.7% |
每股收益（稀释后）APLSBOH
| Q1 26 | — | $1.30 | ||
| Q4 25 | $-0.40 | $1.40 | ||
| Q3 25 | $1.67 | $1.20 | ||
| Q2 25 | $-0.33 | $1.06 | ||
| Q1 25 | $-0.74 | $0.97 | ||
| Q4 24 | $-0.30 | $0.85 | ||
| Q3 24 | $-0.46 | $0.93 | ||
| Q2 24 | $-0.30 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $3.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.9B |
| 总资产 | $1.1B | $23.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSBOH
| Q1 26 | — | $3.3M | ||
| Q4 25 | $466.2M | $946.5M | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | $935.2M | ||
| Q4 24 | $411.3M | $763.6M | ||
| Q3 24 | $396.9M | $1.3B | ||
| Q2 24 | $360.1M | $925.3M |
总债务APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | — | $558.2M | ||
| Q3 25 | — | $558.2M | ||
| Q2 25 | — | $558.2M | ||
| Q1 25 | — | $558.3M | ||
| Q4 24 | — | $558.3M | ||
| Q3 24 | — | $558.3M | ||
| Q2 24 | — | $560.1M |
股东权益APLSBOH
| Q1 26 | — | $1.9B | ||
| Q4 25 | $370.1M | $1.9B | ||
| Q3 25 | $401.2M | $1.8B | ||
| Q2 25 | $156.3M | $1.7B | ||
| Q1 25 | $164.2M | $1.7B | ||
| Q4 24 | $228.5M | $1.7B | ||
| Q3 24 | $237.1M | $1.7B | ||
| Q2 24 | $264.3M | $1.6B |
总资产APLSBOH
| Q1 26 | — | $23.9B | ||
| Q4 25 | $1.1B | $24.2B | ||
| Q3 25 | $1.1B | $24.0B | ||
| Q2 25 | $821.4M | $23.7B | ||
| Q1 25 | $807.3M | $23.9B | ||
| Q4 24 | $885.1M | $23.6B | ||
| Q3 24 | $901.9M | $23.8B | ||
| Q2 24 | $904.5M | $23.3B |
负债/权益比APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | 0.33× | ||
| Q4 24 | — | 0.33× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $218.3M | ||
| Q3 25 | $108.5M | $38.5M | ||
| Q2 25 | $4.4M | $81.7M | ||
| Q1 25 | $-53.4M | $18.3M | ||
| Q4 24 | $19.4M | $170.9M | ||
| Q3 24 | $34.1M | $-20.3M | ||
| Q2 24 | $-8.3M | $45.7M |
自由现金流APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $184.3M | ||
| Q3 25 | $108.3M | $29.8M | ||
| Q2 25 | $4.4M | $72.6M | ||
| Q1 25 | $-53.4M | $10.2M | ||
| Q4 24 | $19.3M | $161.3M | ||
| Q3 24 | — | $-25.0M | ||
| Q2 24 | $-8.4M | $40.7M |
自由现金流率APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 97.2% | ||
| Q3 25 | 23.6% | 16.3% | ||
| Q2 25 | 2.5% | 41.6% | ||
| Q1 25 | -32.0% | 6.0% | ||
| Q4 24 | 9.1% | 98.8% | ||
| Q3 24 | — | -15.3% | ||
| Q2 24 | -4.2% | 26.0% |
资本支出强度APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 18.0% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 0.0% | 5.2% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 5.9% | ||
| Q3 24 | 0.0% | 2.8% | ||
| Q2 24 | 0.0% | 3.2% |
现金转化率APLSBOH
| Q1 26 | — | — | ||
| Q4 25 | — | 3.58× | ||
| Q3 25 | 0.50× | 0.72× | ||
| Q2 25 | — | 1.71× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | — | -0.50× | ||
| Q2 24 | — | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BOH
| Net Interest Income | $151.0M | 79% |
| Noninterest Income | $41.3M | 21% |
